Friday, September 30, 2022


Biotechnology News Magazine

GSK Prepares US for 2022-23 Flu Season with Over 50 million Influenza Vaccine Doses

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research.

GSK expects to distribute over 50 million doses of its influenza vaccine to the US market, continuing to support annual immunization across the US. Despite increased large-scale public health efforts in the 2021-2022 flu season, vaccination rates were similar to the 2020-2021 season. The US Centers for Disease Control and Prevention (CDC) data from April 2022 also showed significant disparities in vaccination coverage for many age groups and ethnicities.1

“The COVID-19 pandemic has shone a light on health disparities in the US and that there is still much more to be done to close the gap. GSK is committed to working alongside our public health partners to increase education and awareness about annual flu vaccination across the board, but especially in underserved communities of color,” said Temi Folaranmi, Vice President and Vaccines Therapeutic Area Head, US Medical Affairs, GSK.

Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe, and are indicated for patients six months and older in line with CDC recommendations.

CDC recommends an annual flu vaccination for anyone aged six months and older who do not have contraindications. According to CDC, annual influenza vaccinations are the best way to help protect against the flu.2

For egg-based influenza vaccines for the 2022-23 flu season, the World Health Organization and FDA’s Vaccines and Related Biological Products Advisory Committee recommended including an A/Victoria/2570/2019 (H1N1) pdm09-like virus, an A/Darwin/9/2021 (H3N2)-like virus, a B/Austria/1359417/2021 (B/Victoria lineage)-like virus and a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.3

For more information on the flu, click here.


Centers for Disease Control and Prevention. Weekly Flu Vaccination Dashboard. Available at: Accessed July 2022.

Centers for Disease Control and Prevention. About Flu. Available at: Accessed July 2022.

World Health Organization. Recommendations announced for influenza vaccine composition for the 2022-2023 northern hemisphere influenza season. Accessed July 2022.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine